This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JAN JanOne (JAN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About JanOne Stock (NASDAQ:JAN) 30 days 90 days 365 days Advanced Chart Get JanOne alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.90▼$3.4952-Week Range N/AVolume139,500 shsAverage Volume229,417 shsMarket Capitalization$20.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Read More… Receive JAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for JanOne and its competitors with MarketBeat's FREE daily newsletter. Email Address JAN Stock News HeadlinesNew Dayton-based publicly traded company in the works with prominent local leaderOctober 7, 2024 | bizjournals.comJANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTSJuly 12, 2024 | prnewswire.comA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.June 18, 2025 | American Alternative (Ad)JanOne Announces Plan to Enhance Stockholder Value Through Strategic RealignmentJuly 10, 2024 | prnewswire.com3 Fintech Stocks to Sell in July Before They Crash & BurnJuly 8, 2024 | investorplace.comJanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 SigmaJune 26, 2024 | prnewswire.comALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORMJune 25, 2024 | prnewswire.comJanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024June 13, 2024 | prnewswire.comSee More Headlines JAN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of JanOne own? Based on aggregate information from My MarketBeat watchlists, some other companies that JanOne investors own include Meta Platforms (META), NVIDIA (NVDA), Teradyne (TER), Salesforce (CRM), DraftKings (DKNG), fuboTV (FUBO) and Marathon Digital (MARA). Company Calendar Today6/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JAN CIK862861 Webwww.janone.com Phone(702) 997-5968Fax952-930-1800Employees170Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.81 million Net MarginsN/A Pretax MarginN/A Return on Equity-359.71% Return on Assets-70.26% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.15 Sales & Book Value Annual Sales$39.61 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / BookN/AMiscellaneous Outstanding Shares8,980,000Free Float8,707,000Market Cap$20.03 million OptionableNot Optionable Beta2.16 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:JAN) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredPresident Trump Could Soon Unlock Trillions in New WealthIf you think America is broke, think again. These "reserve accounts" are worth trillions... And according t...InvestorPlace | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JanOne Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share JanOne With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.